| Project/Area Number |
16K15108
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
ISHIDA Tatsuhiro 徳島大学, 大学院医歯薬学研究部(薬学系), 教授 (50325271)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
清水 太郎 徳島大学, 大学院医歯薬学研究部(薬学系), 特任助教 (30749388)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | ワクチン / アジュバント / ナノキャリア |
|---|
| Outline of Final Research Achievements |
Antigen delivery to antigen presenting cells (APC) is important for development of cancer vaccine. We have found that second dose PEGylated liposomes were selectively taken up by splenic marginal zone B cell (MZ-B), when they were injected with certain interval. This suggests that if antigen is encapsulated into second dose PEGylated liposome, antigen could be delivered to MZ-B, resulting in enhanced anti-tumor immune responses. In this study, we confirmed that delivery of antigen encapsulated in second dose PEGylated liposomes to MZ-B can enhance antitumor immune responses against primary tumor or transplanted tumor.
|
